/Investor DB

ACORN BIOVENTURES — Full Portfolio

18 tracked investments · listed companies and verified rows first

Addex Therapeuticsaddextherapeutics.comin𝕏NASDAQ: ADXNDec 2021SEC filingmedium confidence

Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.

BiotechHealthtechGeneva

Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)

Board seatIsaac Manke· per SEC Form D · $5.9M raise · filed Dec 2021

Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersSR One Capital Management

Onkure Therapeutics Inconkuretherapeutics.comin𝕏NASDAQ: OKURSeries B · Oct 2024 · $57M

OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.

BiotechDigital HealthHealthtechMedical DevicesBoulder, US

Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)

Board seatIsaac Manke· per SEC Form D

Co-investorsAccess BiotechnologyBoulder VenturesRiverVest Venture PartnersAbingworthNew Enterprise Associates (NEA)Novo Holdings

CG Oncologycgoncology.comin𝕏NASDAQ: CGON

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

Arthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+3 more

Eliem TherapeuticsNASDAQ: CLYMMay 2021

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

BiotechWilmington, US

Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)

BoardAdam Rosenberg(Director)

Co-investorsManta Ray VenturesAccess BiotechnologyIntermediate Capital GroupLifeArc VenturesRA Capital

Q32 Bioq32bio.comin𝕏NASDAQ: QTTBSeries B · Oct 2020 · $60M

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in

Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures+2 more

TrovageneinNASDAQ: CRDF

Trovagene is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor, for treatment of cancers including RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia, with the goal of combining it with standard chemotherapy agents to improve patient outcomes.

BiotechSan Diego, US

Thomas Adams(Executive Officer, Director)Antonius Schuh(Executive Officer, Director)inDavid Robbins(Executive Officer)inSteve Zanibobi(Executive Officer)

BoardGabriele Cerrone(Director)Gary Jacob(Director)

Complexicacomplexica.cominMay 2023✓ verified

Complexica provides AI software for optimizing sales, marketing, and supply chain decisions for enterprise customers.

AI & Machine LearningEnterprise SoftwareLogistics & Supply ChainSaaSAdelaide, AU

Dr. Zbigniew Michalewicz(Chief Scientist)Matt Michalewicz(Chief Executive Officer)in

Co-investorsPerennial Partners

Additiveadditive.aiinOct 2024 · $11Macquired by Thomson Reuters

Additive provides a GenAI tool that extracts tax data from K-1, K-3, and related forms (including state forms, 199A, 926, and others), converting PDF tax packages into Excel workpapers or JSON via a web app, Excel add-in, or API.

AI & Machine LearningFintechSaaS

Venky Iyer(Founder)in

Co-investorsMantis CapitalAM VenturesBreakthrough VictoriaElad GilFred EhrsamImmad Akhund+2 more

Conflux Technologyconfluxtechnology.cominOct 2021 · $11M

Conflu-X Technology manufactures thermal management products including cold plates, intercoolers, and liquid cooling solutions for automotive, aviation, data center, defense, and industrial applications.

Advanced ManufacturingData & InfrastructureHardware

Co-investorsAM VenturesBreakthrough Victoria

Fitefite.tvin𝕏Nov 2020 · $22MAcquired

TrillerTV is a direct-to-consumer sports streaming platform operated by Flipps Media, offering live pay-per-view events, subscriptions, and on-demand content featuring combat sports, wrestling, and entertainment programming.

ConsumerMedia & EntertainmentSports TechEncino, US

Co-investorsEarlybird Venture CapitalLAUNCHub VenturesBrightCap Investment Advisor ADPoint72 Ventures

Generogenero.comin𝕏May 2024

Genero is a platform that connects marketers with independent creative talent and production partners on demand.

B2B MarketplacesCreator EconomyMarketing TechMelbourne, AU

Andrew Lane(Founder)in

Co-investorsBrick Capital VenturesEllerston Capital

Liquid Instrumentsliquidinstruments.comin𝕏Sep 2022 · $28.5M

Liquid Instruments develops Moku, a reconfigurable integrated test system for complex research and development applications.

Deep TechDeveloper ToolsEnterprise SoftwareHardware

Daniel Shaddock(CEO)inDanielle Wuchenich(Chief Operating Officer)in

Co-investorsAnzu PartnersBreakthrough VictoriaSignificant VenturesAcorn CapitalLockheed Martin VenturesMA Growth Ventures

Mokumoku.gg𝕏Sep 2022 · $28.5M

Moku creates Moki, a collection of 8887 hand-assembled NFT characters built from 900+ traits, and develops games around them including an AI Fantasy Arena, a snack-combining puzzler, and an async autobattler.

AI & Machine LearningCrypto & Web3Gaming

Bruce Wasicsko(Founder)in

Co-investorsArca FundsBankless VenturesBig Brain HoldingsBlocktower CapitalContango Digital AssetsFormless Capital+4 more

Mx51mx51.comin𝕏Jul 2022 · $32.5M

mx51 provides a white-label merchant dashboard portal that gives payment providers' customers centralized access to real-time transaction reporting, analytics, and service management across multiple payment channels.

Data & InfrastructureEnterprise SoftwareFintechRetail TechSaaSSydney, AU

Victor Zheng(Chief Executive Officer and Co-Founder)inMagnus Hsu(Chief Operating Officer and Co-Founder)inVarghese Mathew(Chief Customer Officer)in

Co-investorsArtesianRampersandAcorn CapitalCultivation CapitalReinventure GroupSixThirty Ventures

Neuron23neuron23.cominMar 2022 · $100M

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.

AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US

Nancy Stagliano(CEO)in

Co-investorsHBM Healthcare InvestmentsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartners+2 more

ONK Therapeuticsonktherapeutics.comSeries A · Jan 2022 · $22M

ONK Therapeutics develops off-the-shelf natural killer (NK) cell therapies for cancer, using a proprietary engineering platform to enhance NK cell function, tumor homing, persistence, and resistance to exhaustion.

Biotech

Redbubbleredbubble.comin𝕏

Redbubble is an online marketplace where independent artists sell their designs printed on products such as apparel and other merchandise.

Creator EconomyE-commerceMarketplaces

Martin Hosking(Founder)inPaul Vanzella(Founder)Peter Styles(Founder)

Co-investorsBlackbird VenturesPiton Capital LLP

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

OnKure, Inc.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.